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Abstract
Background: Ischemic stroke causes a strong inflammatory response that includes T cells, monocytes/macrophages, and
neutrophils. Interaction of these immune cells with platelets and endothelial cells facilitates microvascular dysfunction and
leads to secondary infarct growth. We recently showed that blocking of platelet glycoprotein (GP) receptor Ib improves
stroke outcome without increasing the risk of intracerebral hemorrhage. Until now, it has been unclear whether GPIb only
mediates thrombus formation or also contributes to the pathophysiology of local inflammation.
Methods: Focal cerebral ischemia was induced in C57BL/6 mice by a 60-min transient middle cerebral artery occlusion
(tMCAO). Animals were treated with antigen-binding fragments (Fab) against the platelet surface molecules GPIb (p0p/
B Fab). Rat immunoglobulin G (IgG) Fab was used as control treatment. Stroke outcome, including infarct size and
functional deficits as well as the local inflammatory response, was assessed on day 1 after tMCAO.
Results: Blocking of GPIb reduced stroke size and improved functional outcome on day 1 after tMCAO without
increasing the risk of intracerebral hemorrhage. As expected, disruption of GPIb-mediated pathways in platelets
significantly reduced thrombus burden in the cerebral microvasculature. In addition, inhibition of GPIb limited the
local inflammatory response in the ischemic brain as indicated by lower numbers of infiltrating T cells and
macrophages and lower expression levels of inflammatory cytokines compared with rat IgG Fab-treated controls.
Conclusion: In acute ischemic stroke, thrombus formation and inflammation are closely intertwined (“thrombo-
inflammation”). Blocking of platelet GPIb can ameliorate thrombo-inflammation.
Keywords: Ischemic stroke, Transient middle cerebral artery occlusion, Glycoprotein receptor Ib, Thrombo-
inflammation
Introduction
Ischemic stroke (IS) is a leading cause of death and in-
validity, and its incidence is increasing [1]. The exact
pathophysiologic mechanisms underlying IS are still not
completely understood. While cerebral ischemia has, for
many years, been considered to be a predominantly
thrombotic disease, it is currently widely accepted that
inflammatory processes also play an important role [2].
IS causes a strong inflammatory response, including
transmigration of leukocyte subsets and expression of
inflammatory cytokines [3]. We recently introduced the
interplay between thrombotic and inflammatory mecha-
nisms at the neurovascular unit as a pathophysiologic
concept of thrombo-inflammation [4, 5]. A potential
molecular target linking inflammation and thrombosis
might be the platelet glycoprotein (GP) receptor Ib.
Thrombotic pathways include the binding of GPIb to
endothelial von Willebrand factor for the initial adhesion
of platelets at vascular injury sites. With respect to in-
flammation, GPIb harbors a binding site for the integrin
Mac-1 being expressed on neutrophils and monocytes.
Therefore, GPIb has been shown to be involved in the
recruitment of immune cells [6]. We have previously
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demonstrated that interfering with the early steps of
platelet aggregation and activation via blocking platelet
GPIb reduces infarct volume and improves stroke out-
come in a mouse model of acute experimental stroke,
without increasing the risk of intracerebral hemorrhage
(ICH) [7]. Furthermore, targeting GPIb was also safe and
effective in aged and comorbid mice with IS [8]. There-
fore, blockade of GPIb may be a promising target for hu-
man stroke studies.
The aim of this study was to investigate whether GPIb




In this study, male C57BL/6 wild-type mice were used.
The animals were aged 12–14 weeks. Animal experi-
ments were approved by the legal state authorities
(Regierung von Unterfranken) and performed according
to the recommendations for research in experimental
stroke studies [9], and the current ARRIVE (Animal Re-
search: Reporting of In Vivo Experiments) guidelines
(https://www.nc3rs.org.uk/arrive-guidelines).
Animal treatment
Mice were given 100 μg p0p/B antigen-binding fragment
(Fab) intravenously after a 60-min transient middle cere-
bral artery occlusion (tMCAO) at the time point of fila-
ment removal to inhibit GPIb. The control animals
received 100-μg rat IgG Fab [8].
tMCAO
Focal cerebral ischemia was induced by a 60-min-lasting
tMCAO as described [7]. Twenty-four hours after
tMCAO, the animals were sacrificed and the brains were
cut in three 2-mm-thick coronal sections. The slices
were stained for 20 min at 37 °C with 2% 2,3,5-
triphenyltetrazolium chloride to visualize the infarctions
[10]. Edema-corrected infarct volumes were calculated
by planimetry (ImageJ software, National Institutes of
Health) according to the following equation: Vindir-
ect(mm
3) = Vinfarct × (1 – (VI – VC)/VC); (VI – VC) repre-
sents the volume difference between the ischemic
hemisphere and the control hemisphere and ((VI–VC)/
VC) expresses this difference as a percentage of the con-
trol hemisphere. Global neurologic deficits were assessed
according to the Bederson score [11]. The Grip test
scores were used to monitor motor function and coord-
ination [12]. Occurrence of ICH was macroscopically
assessed on whole brains and again after coronal brain
slices were cut before TTC staining. Researchers and op-
erators were blinded to the experimental groups for all
readout parameters.
Real-time polymerase chain reaction (RT-PCR)
Tissue homogenization, RNA isolation, and real-time PCR
were performed as described recently [5]. Relative gene
expression levels of tumor necrosis factor-α (TNFα) (assay
ID: Mm 00443258_m1, Applied Biosystems), interleukin
(IL)1β (assay ID: Mm 00434228_m1, Applied Biosystems),
and IL6 (assay ID: Mm 00446190_m1, Applied Biosys-
tems) were analyzed with a fluorescent TaqMan technol-
ogy. As an endogenous control Gapdh (TaqMan®
Predeveloped Assay Reagent for gene expression, part
number: 4352339E, Applied Biosystems) was used. PCR
was performed using StepOnePlus™ Real-Time PCR Sys-
tem (Applied Biosystem).
Immunohistochemistry and thrombosis index
Histology and immunohistochemistry were performed
according to standard procedures [13]. Cryoembedded
coronal brain sections (2 mm) were cut into 10-μm-
thick slices. Every tenth slice was used for evaluation.
The following antibodies were used: polyclonal antibody
anti-CD31 (ab9498, abcam), monoclonal antibody
(mAb) anti-GPIX (generated by B. Nieswandt.), mAb
anti-CD11b (MCA711, Serotec), and mAb anti-CD3
(MCA2690A488, BioRad). For quantification of occluded
microvessels, brain slices were stained with hematoxylin
and eosin. Afterwards, the numbers of occluded and
opened vessels per hemisphere were counted to determine
the percentage of occlusions as previously described [13].
All immunohistologic stainings were analyzed and ac-
quired using a Nikon Eclipse 50i microscope.
Statistical analysis
All results are given as mean ± standard error of the
mean except for the Bederson score and the grip test,
which are expressed as ordinal values. For statistical ana-
lysis, the GraphPad Prism 5.0 software package (Graph-
Pad Software) was used. Data were tested for Gaussian
distribution with the D’Agostino and Pearson omnibus
normality test and then analyzed by unpaired, two-tailed
Student’s t test. Scores addressing the functional out-
come were compared using the Mann–Whitney U test.
P < 0.05 was considered statistically significant.
Results
Consistent with our previous results [7, 8], treatment
with anti-GPIb 60 min after tMCAO significantly re-
duced stroke volumes (51.08 ± 9.52 mm3) compared with
IgG Fab-treated controls (90.83 ± 9.07 mm3, P < 0.05) on
day 1 (Fig. 1a, b). Importantly, reduced stroke size in the
anti-GPIb-treated mice translated into better functional
outcome as assessed by the Bederson score (values are
the median with 25th and 75th percentiles, respectively,
in brackets (IgG Fab, 3.0 (2.25, 3.75); GPIb, 2.0 (2.5,
2.25), P < 0.05) (Fig. 1c), but not in the Grip test (IgG
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Fab, 3.0 (3.0, 3.0); GPIb, 3.0 (3.0, 4.0), P > 0.05) (Fig. 1d)).
Analogous to smaller infarct volumes, anti-GPIb treat-
ment inhibited thrombus formation. The number of
GPIX-positive platelet aggregates (number of GPIX-
positive dots, IgG Fab 59.32 ± 5.16; GPIb, 35.07 ± 2.10,
P < 0.01) (Fig. 1e, f ) and ipsilesional occluded brain ves-
sels (percentage of occluded vessels, IgG Fab 44.97 ± 1.9;
GPIb: 33.62 ± 5.42, P < 0.01) (Fig. 1g) was significantly
lower in anti-GPIb-treated animals compared with the
control group. In the next step, we analyzed if the
Fig. 1 Infarct size, neurologic scoring, and brain microvascular thrombosis 24 h after stroke induction. a Representative TTC stainings of three
corresponding coronal brain sections of mice treated with rat IgG Fab (Ctrl Fab) or p0p/B Fab (GPIb) 24 h after induction of tMCAO. Ischemic
infarctions appear white, while vital tissue is stained red. b Infarct volumes as measured by planimetry (n = 8–10/group). c Bederson score and d
Grip test score 24 h after tMCAO (n = 8–10/group). e Representative immunocytologic stainings of platelet aggregates within the vasculature
from the ipsilateral hemisphere of mice, treated with rat IgG Fab (Ctrl Fab) or p0p/B Fab (GpIb) on day 1 after tMCAO. Hoechst depicts cell nuclei,
CD31 stains endothelial cells, and GPIX represents platelet aggregates. Scale bar, 10 μm. f Quantification of ipsilesional glycoprotein IX (GPIX)-
positive aggregates in GPIb-treated mice when compared with control mice. (n = 5 or 6/group). g Quantification of occluded ipsilesional vessels
in hematoxylin–eosin (H&E)-stained brain sections on day 1 after tMCAO (n = 5–6/group). b, f, g, *P < 0.05, **P < 0.01, unpaired Student’s t test. c,
d, *P < 0.05, Mann–Whitney U test
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inhibition of platelet activation, and therefore thrombus
formation, coincides with reduced inflammation. We
demonstrated fewer ipsilesional activated microglia/mac-
rophages (Fig. 2a–e, P < 0.05) and T cells (Fig. 2f–i, P <
0.05 and < 0.001) after treatment with anti-GPIb. Cytokine
expression analysis revealed significantly less TNFα in the
basal ganglia (relative gene expression, IgG Fab 13.33 ±
3.81; GPIb, 2.49 ± 0.89, P < 0.05) and a tendency towards
Fig. 2 Quantification of immune cell accumulation and relative cytokine gene expression in the infarcted hemisphere at day 1 after stroke. a
Representative CD11b-immunoreactivity 24 h after tMCAO of mice treated with rat IgG Fab (Ctrl Fab) or p0p/B Fab (GPIb). Scale bar, 100 μm. c
Schematic view of the brain regions analyzed to quantify the density of immune cells per mm2. b, d, e Quantification of CD11b-positive cells per
slice and CD11b-positive cells/mm2 in different cortical and basal ganglial regions in the ipsilateral hemisphere at day 1 (n = 5/group). f Representative
immunocytologic stainings of brain-infiltrating CD3-positive T lymphocytes on day 1 after tMCAO of mice, treated with rat IgG Fab (Ctrl Fab) or p0p/B
Fab (GPIb). Scale bar, 25 μm. g–i Quantification of CD3-positive cells per slice and CD3-positive cells/mm2 in different cortical and basal ganglial regions
in the ipsilateral hemisphere at day 1 (n = 5/group). j, k Relative gene expression of tumor necrosis factor-α (TNFα), interleukin-1β (IL1β), and
interleukin-6 (IL6) in the cortical and basal ganglia ischemic hemispheres of mice, treated with rat IgG Fab (Ctrl Fab) or p0p/B Fab (GPIb) (n = 6/group).
*P < 0.05, ***P < 0.001, unpaired Student’s t test
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reduced expression in the cortex as well as reduced ex-
pression of IL1β and IL6 in both regions (Fig. 2j, k).
Discussion
In the present study, we identified reduced thrombo-
inflammation to be associated with the stroke-protective
properties of anti-GPIb treatment in mice. Importantly,
in our current and previous studies, GPIb blockade re-
duced stroke volumes and significantly improved neuro-
logic deficits in a clinically relevant setting, when
injected 60 min after tMCAO [7, 8]. Of interest, stroke
protection was not accompanied by ICH complications.
The observation of an antithrombotic effect when target-
ing GPIb in an in vivo experimental stroke model is con-
gruent with in vitro findings of platelet thrombus
formation under flow [14]. GPIb has a key function in
thrombotic processes, as it is essential for the initial ad-
hesion of platelets to the vessel wall under high shear
rates [15]. Furthermore, GPIb harbors a binding site for
Mac-1. Mac-1 has been shown to be involved in the ad-
hesion of leukocytes to platelets, and leukocyte-platelet
complexes might promote inflammation [16]. Therefore,
GPIb/Mac-1 interactions might provide a potential
mechanistic link between thrombosis and inflammation
[4, 6]. Our finding that blocking GPIb reduced the num-
ber of ipsilesional leukocytes after experimental stroke
strongly supports the concept of thrombo-inflammation
and is in accordance with a previous investigation that
found GPIb to be involved in the recruitment of im-
mune cells in a model of acute peritonitis [6]. Interest-
ingly, besides reduced numbers of monocytes, the
number of CD4-positive T cells invading the ipsilateral
hemisphere was also significantly reduced in this study.
Importantly, not only the overall number but also the
density of infiltrating immune cells in brain areas that
are infarcted in both treatment groups was reduced, ar-
guing against an unspecific effect related to smaller in-
farct volumes.
Tumor necrosis factor, interleukin-1, and interleukin-6
are potent inflammatory cytokines that have been shown
to modulate tissue injury in experimental stroke [17].
There is evidence that tumor necrosis factor and
interleukin-1 are produced in the ischemic hemispheres
of rodents by CD11b-positive cells [18–20]. This is in
good agreement with our data revealing reduced TNFα
and IL1β expression especially within the basal ganglia
regions where blocking of platelet GPIb significantly re-
duced the number of CD11b-positive cells/mm2.
It is widely accepted that T cells have a detrimental
role in the acute phase of IS [21, 22]. Brain ischemia rap-
idly activates the cerebral microvasculature [23]. Endo-
thelial adhesion molecules become rapidly upregulated,
and damaged vessels expose subendothelial matrix pro-
teins to the bloodstream, thereby providing an interface
for T cell–endothelial as well as platelet–endothelial and
T cell–platelet interdependencies. Our mechanistic stud-
ies recently revealed that T cells promote stroke due to
interactions with the activated endothelium. Thereby, T
cells cause microvascular dysfunction and further in-
crease thrombus formation during the early phase after
tMCAO [5, 13, 24]. The present study shows, for the
first time, that targeting platelets by blocking their early
adhesion to vessel walls [25] impacts T cell driven in-
flammatory processes after stroke.
In summary, our study confirms that in acute IS,
thrombus formation and inflammation are closely inter-
twined. Blocking of platelet GPIb can ameliorate thrombo-
inflammation.
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